13.48
-0.25(-1.82%)
Currency In USD
| Previous Close | 13.73 |
| Open | 13.82 |
| Day High | 14.09 |
| Day Low | 13.42 |
| 52-Week High | 18.38 |
| 52-Week Low | 8.24 |
| Volume | 2.14M |
| Average Volume | 922,725 |
| Market Cap | 878.56M |
| PE | -3.59 |
| EPS | -3.75 |
| Moving Average 50 Days | 14.72 |
| Moving Average 200 Days | 12.88 |
| Change | -0.25 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $731.02 as of June 20, 2025 at a share price of $13.48. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $1,151.15 as of June 20, 2025 at a share price of $13.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
GlobeNewswire Inc.
Jun 17, 2025 11:00 AM GMT
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reducti
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
GlobeNewswire Inc.
May 24, 2025 8:30 AM GMT
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA